GlobalData Plc

The Canadian pharmaceutical market is set to grow from $22.6 billion in 2016 to around $25 billion by 2021, representing a compound annual growth rate of 2%, according to GlobalData, a recognized leader in providing business information and analytics.

The company’s latest report states that Canada has a strong pharmaceutical industry footprint and is one of the leading locations for clinical trials. Global companies and biotechnology firms have increased their investments in academic industrial translational activities in Canada in recent years, and major pharmaceutical companies conduct a significant portion of their clinical trials there. It is this strong R&D and clinical trial environment that is driving the growth of the market, along with Canada’s increasing elderly population.

The country’s pharmaceutical industry is shifting towards externalized R&D via partnerships and collaborations, with the government setting up programs such as the Business-led Networks of Centres of Excellence (BL-NCEs), Centres of Excellence for Commercialization of Research (CECR) and other innovation initiatives such as the Structural Genomics Consortium.

The extensive network of academic health institutions and research centres conducting this R&D includes 17 medical schools, approximately 40 groupings of academic healthcare organizations and about 13,600 researchers, as well as strategically focused research networks. Companies such as Johnson & Johnson and Teva have partnered with such academic healthcare organizations in order to benefit from the globally-recognized quality and expertise of Canada’s research clinicians.

In 2016, the value of the generic pharmaceutical market was $6.2 billion, with generic drugs accounting for around 70% of prescriptions in Canada, compared with 89% in the US. However, generic drug sales account for only 22.4% of the overall pharmaceutical market. The use of generic medicines saved nearly $20 billion for the government in 2016, and GlobalData expects the market to continue to grow as the government promotes generics usage and as quality perception improves among patients.

– Information based on GlobalData’s report: CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Canada.

Related Intelligence

Want more Insight like this?

Our interactive subscription platform has the most comprehensive data and analysis in your industry.

Request a Demo

Related Consulting

How can we help your business?

Our consultants are skilled in every specialist market niche to deliver solutions specifically designed for your individual requirements.

Request a Callback

    Press Release Healthcare

    Late-stage CKD-induced comorbidity therapeutics market to reach $10.5bn by 2026

    Sales for chronic kidney disease (CKD)-induced hyperparathyroidism (HPT), hyperphosphatemia (HP), and hyperkalemia (HK) therapeutics were estimated to be $4.2bn across the seven major markets (7MM*) in 2016. This is expected to grow to $10.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 9.5%, according to GlobalData, a leading data and analytics company.

    Press Release Healthcare

    Majority of oncology clinical trials in China failed to meet enrolment targets

    The majority of oncology clinical trials in China that had a start date between 1 January 2012 and 31 December 2017 failed to meet the planned enrolment targets, according to GlobalData, a leading data and analytics company. The company identified and analyzed enrollment efficiencies of 324 clinical trials during the period and found that on...

    Press Release Healthcare

    Need for supportive care in oncology will increase during the next decade

    The need for effective supportive care in oncology will increase in the next decade as patients continue to live longer and cancer progresses to become more like a chronic disease. This includes the need for chemotherapy-related conditions, as chemotherapy will remain the backbone of cancer therapy for the foreseeable future, observes GlobalData, a leading data and analytics company.

    Press Release Healthcare

    World Cancer Day: What will 2018 mean for cancer research and treatment?

    The theme of this year’s World Cancer Day held on 4th February of “We can. I can.” aimed to reinforce the public message that all individuals and groups can play their part in reducing the global burden of cancer. Indeed in recent years many events have involved collaborations between traditional drug developers, cancer treatment professionals and those of varying disciplines. Examples include the IBM Watson supercomputer which is helping physicians make treatment decisions and the development of other databases such as ASCO’s CancerLinQ which assists oncologists in monitoring and analyzing patient data.

    Press Release Healthcare

    Melanoma sales are projected to rise to $5.5bn in 2026

    The value of the melanoma market was estimated to be $3.3bn across the seven major markets (7MM*) in 2016. This is expected to grow to $5.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 5.3%, according to GlobalData, a leading data and analytics company.

Media Enquiries

If you are a member of the press or media and require any further information, please get in touch, as we’re very happy to help.
PhoneEMEA: +44 207 832 4399
PhoneAPAC: +91 40 6616 6809
Onlinecontact online

56% of #consumers are concerned about the impact of diet. Join us for more insight @incosmetics #cosmetics #trends…